Time filter

Source Type

Amdekar Y.K.,Jaslok Hospital and Research Center | Lalwani S.K.,Bharati Vidyapeeth Deemed University | Bavdekar A.,Kem Hospital Research Center | Balasubramanian S.,CHILDS Trust Medical Research Foundation | And 10 more authors.
Pediatric Infectious Disease Journal | Year: 2013

Background: The childhood burden of disease attributable to Streptococcus pneumoniae is particularly high in India. The immunogenicity and safety of 13-valent pneumococcal conjugate vaccine (PCV13) were compared with 7-valent pneumococcal conjugate vaccine (PCV7) in a randomized, active-controlled, double-blind trial conducted at 12 sites in India. Methods: Healthy infants received PCV13 or PCV7 at 6, 10, and 14 weeks of age (infant series) and at 12 months of age (toddler dose), along with routine pediatric vaccinations. Immunoglobulin G responses against the 13 pneumococcal serotypes were evaluated 1 month after the infant series and after the toddler dose. Pertussis and poliomyelitis immune responses were assessed 1 month after the infant series. Safety and tolerability also were assessed. Results: The immunogenicity results for the 7 common serotypes and the concomitant vaccines (whole-cell pertussis and oral poliovirus) were similar for subjects receiving PCV13 and subjects receiving PCV7. Immune responses to the 6 additional serotypes were higher in the PCV13 group compared with the PCV7 group. PCV13 and PCV7 had similar safety and tolerability profiles. Conclusions: PCV13 has immunogenicity similar to PCV7 in response to the 7 common serotypes, and has generally higher immunogenicity in response to the 6 additional serotypes. PCV13 may provide added protection against pneumococcal disease caused by the additional 6 serotypes and does not interfere with immune responses to whole-cell pertussis and oral poliovirus vaccines. PCV13 has an acceptable safety profile in both infants and toddlers, comparable with that of PCV7. Copyright © 2013 by Lippincott Williams & Wilkins.

Meenakshi B.,Manonmaniam Sundaranar University | Venkataraman R.,Sri Paramakalyani College | Janakiraman L.,CHILDS Trust Medical Research Foundation
Journal of Pediatric Biochemistry | Year: 2013

Aim: To study the serum copper, zinc and selenium levels in children with iron deficiency anemia in comparison with healthy controls. Methods: A prospective case control study was conducted over a period of 18 months in a tertiary care children's hospital to study the serum copper, zinc and selenium levels in children with iron deficiency anemia in comparison with healthy controls. A total of 35 children with anemia and 35 controls were enrolled for the study. Results: The normal serum copper, zinc and selenium levels were 510°C-1530 μg/L, 600°C-1200 μg/L and 55°C-130 μg/L respectively. Mean serum copper, zinc and selenium levels in children with anemia were 1589 ± 529.7, 568 ± 252.8 and 71 ± 41.5 μg/L respectively and in controls the levels were 892 ± 368.3, 890 ± 213.9 and 102 ± 39.2 μg/L (P < 0.05) showing decreased serum zinc and selenium levels and increased copper levels in children with iron deficiency anemia than controls. Conclusion: This study shows that serum zinc and selenium levels are decreased and serum copper levels are increased in children with iron deficiency anemia than controls.

Mathangi Ramakrishnan K.,CHILDS Trust Medical Research Foundation | Babu M.,CHILDS Trust Medical Research Foundation | Lakshmi Madhavi M.S.,Cavin kare Research Center
Annals of Burns and Fire Disasters | Year: 2015

Keloid scars continue to pose a challenge to clinicians as the treatment armamentarium lacks a formidable agent to tackle them. We have undertaken an in vitro study based on the mechanism of action of Vitamin D3 and quercetin on isolated keloid fibroblasts. Dose-dependent action on the reduction of cellular proliferation, collagen synthesis and induction of apoptosis by Vitamin D3 and quercetin are analyzed and probable mechanism of action is elaborated. This study thus opens up newer avenues in tackling keloid scars effectively. © 2015, Mediterranean Club for Burns and Fire Disasters. All rights reserved.

Suresh N.,CHILDS Trust Medical Research Foundation | Thiruvengadam V.,CHILDS Trust Medical Research Foundation
Paediatrics and International Child Health | Year: 2013

Cytomegalovirus (CMV) infection in immunocompetent hosts is usually benign and does not require antiviral therapy. Rarely, however, it can be severe and life-threatening. Two immunocompetent infants with severe acquired CMV infection are reported who responded dramatically to ganciclovir with no observed side-effects. Ganciclovir should be considered in the rare instance of severe CMV infection in immunocompetent children. © W. S. Maney & Son Ltd 2013.

Balasubramanian S.,CHILDS Trust Medical Research Foundation | Dhanalakshmi K.,CHILDS Trust Medical Research Foundation | Amperayani S.,CHILDS Trust Medical Research Foundation
Indian Pediatrics | Year: 2013

Vitamin D deficiency has emerged as a significant public health problem throughout the world. Even in the Indian context,it has been reported to be present in majority of children in spite of wide availability of sunlight. Recent guidelines have defined vitamin D status as severe deficiency, deficiency, sufficiency and risk for toxicity as 25(OH)D levels <5, <15, >20 and >50ng/mL, respectively.The manifestations of deficiency may vary from hypocalcemic seizures, tetany in infancy and adolescence to florid rickets in toddlers. Treatment is necessary for all individuals with deficiency whether symptomatic or not and consists of vitamin D supplementation as Stoss therapy or daily or weekly oral regimens with equal efficacy and safety, combined with calcium supplements. Routine supplementation starting from newborn period is being increasingly endorsed by various international organizations. Prevention by sensible sunlight exposure, food fortification and routine supplementation are the currently available options for tackling this nutritional deficiency. © 2013 Indian Academy of Pediatrics.

Discover hidden collaborations